Overview

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Subjects with epilepsy with a documented photoparoxysmal response to intermittent photic stimulation (IPS) will participate. Four subjects will be enrolled at each dose level and will receive a single dose of placebo and a single dose of ICA-105665 during the study, each followed by intermittent photic stimulation. The effects of ICA-105665 on the photoparoxysmal electroencephalography (EEG) response of each group will be reviewed before the dose is selected for each subsequent group of subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer